The goal of this project is to identify critical negative regulators of T cell activity in highly immunosuppressive tumor microenvironments. We have developed a highly novel approach that enables in vivo discovery of novel therapeutic targets using next generation sequencing technologies. The project involves mechanistic characterization of critical negative regulators and evaluation of their therapeutic potential for adoptive T cell therapies, including chimeric antigen receptors (CAR). Requirements are a recent PhD in immunology, cancer biology or molecular biology.
Please send CV and names/email addresses of three references to kai_wucherpfennig@dfci.harvard.edu.
Please visit our lab website for more information: http://research4.dfci.harvard.edu/tcell/ 　

中国-博士人才网发布